ReciBioPharm and MIT are in the midst of developing fully integrated and digitally controlled production lines for xRNA. Through this project we will develop an innovative production stream from DNA to Drug Product—IVT to fill-finish; compatible with a wide range of xRNA modalities and nanoparticle formulations; integrated process analytical technologies; include digital twins to accelerate development time; and include machine-learning for predictive control.